Literature DB >> 11085811

Do B cells influence disease progression in chronic synovitis? Lessons from primary hypogammaglobulinaemia.

N Pipitone1, V A Jolliffe, A Cauli, D G Scott, C Pitzalis.   

Abstract

We describe a 62-yr-old male patient with primary hypogammaglobulinaemia (PH) who fulfilled the 1987 American Rheumatism Association/American College of Rheumatology revised diagnostic criteria for rheumatoid arthritis (RA) but, despite persistent symmetrical synovitis, did not develop erosions. Virology studies and blood and synovial fluid (SF) cultures were consistently negative; a search for crystals in the SF was unrevealing. Peripheral blood (PB) B cells were absent, whilst the PB CD3(+) cell count was normal. The ratio of naive (CD45RA(+)) to memory (CD45R0(+)) cells was also normal (1:1) but the CD4:CD8 ratio was reversed. To our knowledge, this is the first report which combines the immunophenotypic analysis of the PB with that of the SF and synovial membrane (SM). This confirmed the absence of B cells and the reversed CD4:CD8 ratio. However, as in other chronic arthropathies, the SF and SM cellular infiltrate consisted almost exclusively of memory T cells, consistent with the preferential localization of this subset to inflamed tissues. This case indicates that synovitis can proceed persistently in the absence of B cells and that the migratory mechanisms of T cells are not altered. However, the case suggests that the absence of B cells and negativity for rheumatoid factor, combined with an increased presence of CD8(+) (suppresser/cytotoxic) T cells in the joint, might contribute to the non-erosive nature of the synovitis.

Entities:  

Mesh:

Year:  2000        PMID: 11085811     DOI: 10.1093/rheumatology/39.11.1280

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  1 in total

1.  Arthritis as a presenting symptom in a hypogammaglobulinemic patient with thymectomy.

Authors:  Omür Ardeniz; Sezgin Vatansever; Uğur Musabak; Kenan Aksu; Aytül Sin; Ali Kokuludağ
Journal:  Rheumatol Int       Date:  2006-08-25       Impact factor: 2.631

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.